Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1949 1
1952 1
1960 1
1964 2
1971 1
1989 1
1993 3
1994 2
1995 1
1996 2
1997 3
1998 7
1999 8
2000 6
2001 7
2002 12
2003 9
2004 11
2005 14
2006 11
2007 13
2008 5
2009 5
2010 9
2011 5
2012 5
2013 2
2014 5
2015 6
2016 4
2017 2
2018 2
2019 2
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16513623

154 results

Results by year

Filters applied: . Clear all
Page 1
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S. Jamar F, et al. Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):510-8. doi: 10.1007/s00259-003-1117-1. Epub 2003 Feb 12. Eur J Nucl Med Mol Imaging. 2003. PMID: 12582815 Clinical Trial.
Reducing renal uptake of radiolabeled peptides using albumin fragments.
Vegt E, van Eerd JE, Eek A, Oyen WJ, Wetzels JF, de Jong M, Russel FG, Masereeuw R, Gotthardt M, Boerman OC. Vegt E, et al. J Nucl Med. 2008 Sep;49(9):1506-11. doi: 10.2967/jnumed.108.053249. Epub 2008 Aug 14. J Nucl Med. 2008. PMID: 18703613 Free article.
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Göke B, Weber MM, Wiedenmann B, Pauwels S, Haus U, Bouterfa H, Bartenstein P. Helisch A, et al. Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1386-92. doi: 10.1007/s00259-004-1561-6. Epub 2004 Jun 3. Eur J Nucl Med Mol Imaging. 2004. PMID: 15175836 Clinical Trial.
154 results